Depression, aggression, and other behavioral changes have correlations with the leukotriene receptor antagonists. Careful monitoring is necessary for patients treated with leukotriene receptor antagonists.

Zafirlukast may cause severe but rare acute liver damage. It is a major substrate of the cytochrome P450 CYP2C9 enzyme. Patients receiving concomitant therapy with drugs such as alpelisib, dabrafenib, enzalutamide, erythromycin, loxapine, lumacaftor, rifapentine, terfenadine, and warfarin require monitoring for potential drug interactions.